

Full-Year Performance Overview

Almirall surpassed guidance for 2024 - entering an era of sustained growth and further advancing its Medical Dermatology pipeline



2024 was an important year for Almirall as European leader in Medical Dermatology. Our double-digit sales growth and increased profitability demonstrate that our strategy is working and that our teams are delivering. In 2024 we achieved net sales growth of 10.2% and increased our total EBITDA by 10.6%, which was largely driven by our European dermatology business and our biologics. We continued to progress our exciting pipeline in medical dermatology by investing 12.6% of Net Sales in R&D and explore external opportunities for early and mid-stage assets.

Carlos Gallardo,
Almirall's Chairman and CEO

Key Financial Highlights

Net Sales
€985.7 MM
(+10.2% YoY)

Total EBITDA
€192.6 MM
(+10.6% YoY)


Gross Margin
64.7%

Total Sales Dermatology

Net Sales: €548.1 MM

US	Europe	RoW
10%	88%	2%

Net Sales breakdown



Driving Innovation in R&D



Investment
€124.2 M
(12.6% of sales)



Pipeline
13
active projects



Global Rights
4
early-stage promising assets



Partnerships
23
innovative collaborations to access cutting-edge therapeutic modalities

